These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17073576)

  • 1. Bioactivation and hepatotoxicity of nitroaromatic drugs.
    Boelsterli UA; Ho HK; Zhou S; Leow KY
    Curr Drug Metab; 2006 Oct; 7(7):715-27. PubMed ID: 17073576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity.
    Smith KS; Smith PL; Heady TN; Trugman JM; Harman WD; Macdonald TL
    Chem Res Toxicol; 2003 Feb; 16(2):123-8. PubMed ID: 12588182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide.
    Boelsterli UA
    Drug Saf; 2002; 25(9):633-48. PubMed ID: 12137558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial permeability transition as a source of superoxide anion induced by the nitroaromatic drug nimesulide in vitro.
    Tay VK; Wang AS; Leow KY; Ong MM; Wong KP; Boelsterli UA
    Free Radic Biol Med; 2005 Oct; 39(7):949-59. PubMed ID: 16140214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolcapone in the management of Parkinson's disease.
    Leegwater-Kim J; Waters C
    Expert Opin Pharmacother; 2006 Nov; 7(16):2263-70. PubMed ID: 17059382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioactivation of flutamide metabolites by human liver microsomes.
    Kang P; Dalvie D; Smith E; Zhou S; Deese A; Nieman JA
    Drug Metab Dispos; 2008 Jul; 36(7):1425-37. PubMed ID: 18411402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolcapone: an efficacy and safety review (2007).
    Olanow CW; Watkins PB
    Clin Neuropharmacol; 2007; 30(5):287-94. PubMed ID: 17909307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolcapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations.
    Spahr L; Rubbia-Brandt L; Burkhard PR; Assal F; Hadengue A
    Dig Dis Sci; 2000 Sep; 45(9):1881-4. PubMed ID: 11052337
    [No Abstract]   [Full Text] [Related]  

  • 9. Underlying mitochondrial dysfunction triggers flutamide-induced oxidative liver injury in a mouse model of idiosyncratic drug toxicity.
    Kashimshetty R; Desai VG; Kale VM; Lee T; Moland CL; Branham WS; New LS; Chan EC; Younis H; Boelsterli UA
    Toxicol Appl Pharmacol; 2009 Jul; 238(2):150-9. PubMed ID: 19442681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs.
    Fischer JJ; Michaelis S; Schrey AK; Graebner OG; Glinski M; Dreger M; Kroll F; Koester H
    Toxicol Sci; 2010 Jan; 113(1):243-53. PubMed ID: 19783845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy.
    Borges N
    Drug Saf; 2003; 26(11):743-7. PubMed ID: 12908845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substrate selectivity of human aldehyde oxidase 1 in reduction of nitroaromatic drugs.
    Ogiso T; Fukami T; Mishiro K; Konishi K; Jones JP; Nakajima M
    Arch Biochem Biophys; 2018 Dec; 659():85-92. PubMed ID: 30367827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nimesulide-induced electrophile stress activates Nrf2 in human hepatocytes and mice but is not sufficient to induce hepatotoxicity in Nrf2-deficient mice.
    Kale VM; Hsiao CJ; Boelsterli UA
    Chem Res Toxicol; 2010 May; 23(5):967-76. PubMed ID: 20405857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolcapone and fulminant hepatitis.
    Assal F; Spahr L; Hadengue A; Rubbia-Brandt L; Burkhard PR
    Lancet; 1998 Sep; 352(9132):958. PubMed ID: 9752821
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of the cytotoxicity of the nitroaromatic drug flutamide to its cyano analogue in the hepatocyte cell line TAMH: evidence for complex I inhibition and mitochondrial dysfunction using toxicogenomic screening.
    Coe KJ; Jia Y; Ho HK; Rademacher P; Bammler TK; Beyer RP; Farin FM; Woodke L; Plymate SR; Fausto N; Nelson SD
    Chem Res Toxicol; 2007 Sep; 20(9):1277-90. PubMed ID: 17702527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism for the hepatotoxicity of the antiandrogen, nilutamide. Evidence suggesting that redox cycling of this nitroaromatic drug leads to oxidative stress in isolated hepatocytes.
    Fau D; Berson A; Eugene D; Fromenty B; Fisch C; Pessayre D
    J Pharmacol Exp Ther; 1992 Oct; 263(1):69-77. PubMed ID: 1403804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nimesulide and hepatic adverse effects: roles of reactive metabolites and host factors.
    Boelsterli UA
    Int J Clin Pract Suppl; 2002 Jul; (128):30-6. PubMed ID: 12166617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-time concurrent monitoring of apoptosis, cytosolic calcium, and mitochondria permeability transition for hypermulticolor high-content screening of drug-induced mitochondrial dysfunction-mediated hepatotoxicity.
    Kim JA; Han E; Eun CJ; Tak YK; Song JM
    Toxicol Lett; 2012 Oct; 214(2):175-81. PubMed ID: 22981620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of nilutamide by NO synthases: implications for the adverse effects of this nitroaromatic antiandrogen drug.
    Ask K; Dijols S; Giroud C; Casse L; Frapart YM; Sari MA; Kim KS; Stuehr DJ; Mansuy D; Camus P; Boucher JL
    Chem Res Toxicol; 2003 Dec; 16(12):1547-54. PubMed ID: 14680368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes.
    Kang P; Dalvie D; Smith E; Zhou S; Deese A
    Drug Metab Dispos; 2007 Jul; 35(7):1081-8. PubMed ID: 17403914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.